Cargando…

Effects of dalteparin on anti‐Xa activities cannot be predicted in critically ill COVID‐19 patients

Critically ill COVID‐19 patients are at high risk of thromboembolic events despite routine‐dosed low‐molecular‐weight heparin thromboprophylaxis. However, in recent randomized trials increased‐intensity thromboprophylaxis seemed futile and possibly even harmful. In this explorative pharmacokinetic (...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Heijden, Charlotte D. C. C., ter Heine, Rob, Kooistra, Emma J., Brüggemann, Roger J., Walburgh Schmidt, Jesper W. J., de Grouw, Elke P. L. M., Frenzel, Tim, Pickkers, Peter, Leentjens, Jenneke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305530/ https://www.ncbi.nlm.nih.gov/pubmed/34965610 http://dx.doi.org/10.1111/bcp.15208

Ejemplares similares

Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies
por: Wasmann, Roeland E., et al.
Publicado: (2020)

Anti-Xa activity after subcutaneous administration of dalteparin in intensive care unit patients with and without subcutaneous oedema
por: Rommers, M, et al.
Publicado: (2005)

An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients
por: Wallenburg, Eveline, et al.
Publicado: (2022)

Correction to: An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients
por: Wallenburg, Eveline, et al.
Publicado: (2022)

Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study
por: Rommers, Mirjam K, et al.
Publicado: (2006)

Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility
por: Gieling, Emilie M., et al.
Publicado: (2020)

High unbound flucloxacillin fraction in critically ill patients
por: Wallenburg, Eveline, et al.
Publicado: (2021)

Anti-Xa activities following 5,000 IU and 7,500 IU of s.c. dalteparin in critically ill patients and 5,000 IU in medical patients: a prospective randomized study
por: Heinz, GH, et al.
Publicado: (2013)

Gamma-Irradiated Bacille Calmette-Guérin Vaccination Does Not Modulate the Innate Immune Response during Experimental Human Endotoxemia in Adult Males
por: Hamers, Linda A. C., et al.
Publicado: (2015)

Does dalteparin PROTECT better than heparin?
por: Przybysz, Thomas, et al.
Publicado: (2011)

In vitro Effect of Dalteparin and Argatroban on Hemostasis in Critically Ill Sepsis Patients with New-Onset Thrombocytopenia
por: Nygaard, Søren, et al.
Publicado: (2023)

The Effects of Orally Administered Beta-Glucan on Innate Immune Responses in Humans, a Randomized Open-Label Intervention Pilot-Study
por: Leentjens, Jenneke, et al.
Publicado: (2014)

Management of venous thromboembolism in patients with cancer: role of dalteparin
por: Linkins, Lori-Ann
Publicado: (2008)

Dalteparin-sodium: Chest wall haematoma: case report
Publicado: (2022)

Bilateral spontaneous, simultaneous lower extremity hematomas in a patient on dalteparin()
por: Daggett, J.R., et al.
Publicado: (2013)

Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients
por: Li, Guowei, et al.
Publicado: (2015)

Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism
por: Damle, Bharat, et al.
Publicado: (2020)

Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer
por: Otten, Leila S., et al.
Publicado: (2022)

Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors
por: Cook, Deborah, et al.
Publicado: (2008)

An XA21-Associated Kinase (OsSERK2) Regulates Immunity Mediated by the XA21 and XA3 Immune Receptors
por: Chen, Xuewei, et al.
Publicado: (2014)

Evidence‐based rationale for low dose nivolumab in critically ill patients with sepsis‐induced immunosuppression
por: van den Haak, Demy A. C., et al.
Publicado: (2023)

A comparative study of dalteparin and unfractionated heparin in patients with unstable angina pectoris
por: Amane, Hanmant S., et al.
Publicado: (2011)

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
por: Trujillo‐Santos, Javier, et al.
Publicado: (2022)

Use of anti-Xa factor titration as efficacy marker of enoxaparin in critically ill patients
por: Lage, S, et al.
Publicado: (2006)

Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series
por: Payen, Didier, et al.
Publicado: (2019)

Prospective validation of a model‐informed precision dosing tool for vancomycin in intensive care patients
por: ter Heine, Rob, et al.
Publicado: (2020)

Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients
por: Martial, Lisa C., et al.
Publicado: (2017)

Effect of a Direct Thrombin Inhibitor Compared with Dalteparin and Unfractionated Heparin on Human Osteoblasts
por: Winkler, Tobias, et al.
Publicado: (2011)

Hypoxia and the Anticoagulants Dalteparin and Acetylsalicylic Acid Affect Human Placental Amino Acid Transport
por: Kleppa, Marc-Jens, et al.
Publicado: (2014)

Structural Characterization of the Low-Molecular-Weight Heparin Dalteparin by Combining Different Analytical Strategies
por: Bisio, Antonella, et al.
Publicado: (2017)

Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers
por: Lee, Jang Ho, et al.
Publicado: (2019)

Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies
por: Jansen, Anouk M. E., et al.
Publicado: (2023)

The value of D-dimer to predict pulmonary embolism in critically ill COVID-19 patients
por: van den Berg, M.J.W., et al.
Publicado: (2021)

Enhanced effect of fibroblast growth factor-2-containing dalteparin/protamine nanoparticles on hair growth
por: Takabayashi, Yuki, et al.
Publicado: (2016)

Dalteparin as a Novel Therapeutic Agent to Prevent Diabetic Encephalopathy by Targeting Oxidative Stress and Inflammation
por: Zeinivand, Motahareh, et al.
Publicado: (2020)

Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism
por: de Jong, Lisa A, et al.
Publicado: (2020)

Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019
por: Mohamed, Adham, et al.
Publicado: (2022)

Xa tantlin lisantiago /
por: Ibarra, José Xochihua
Publicado: (1993)

Coagulation Factor Xa
por: Brown, Mark A., et al.
Publicado: (2013)

The right time to measure anti-Xa activity in critical illness: pharmacokinetics of therapeutic dose nadroparin
por: Sytema, Jelmer G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9f6b2vom8ddchhmmjvlgm263hu